Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2010

View Archived Issues

INCB-7839 improves response to trastuzumab in metastatic HER2+ breast cancer

[131I]-Basiliximab is safe and induces responses in patients with refractory lymphoma

DanDrit's MelCancerVac cancer vaccine active in phase II trial in colorectal cancer

FDA grants emergency use authorization to Cepheid's Xpert Flu A Panel

Phase II investigation of diabetes treatment EGT-0001442 begins

EXC-001 enters phase II trials for improving surgery-related scar appearance

Novel inhibitors of IAP inhibitors claimed by the University of Michigan

IRM discovers novel ALK inhibitors for cancer therapy

Glaxo Wellcome discloses NK1 receptor antagonists for sleep disorders

Novel erythromycin derivatives for respiratory disorders in development at GSK

Pearl reports results from phase IIa trial of formoterol inhalation aerosol in COPD

Dendritic cells do not enhance activity of canarypox-HIV vaccine

Dh-404 reduces oxidative stress and may be beneficial to treat heart disease

UK scientists divulge novel B-Raf kinase inhibitors for cancer therapy

Keryx announces SPA agreement with FDA on phase III Zerenex trials in ESRD

Luitpold acquires PharmaForce

Novartis agreement to supply rhPDGF-BB to BioMimetic amended

Gilead's Quad regimen meets primary objective in phase II trial in HIV-infected adults

Takeda discloses novel SMO antagonists for cancer therapy

Novo Nordisk and Combine to collaborate in the field of autoimmune diseases

Phase II trial of AZX-100 for dermal scarring completes enrollment

FDA accepts development path for ARYx Therapeutics' anticoagulant tecarfarin

Encouraging top-line results reported from ACCORD COPD I study of aclidinium

BioMarin's amifampridine phosphate approved in the EU for LEMS

OncoMethylome and Roche to collaborate on phase III Avastin trial in glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...